Epstein-Barr virus (EBV) is a member of the Herpesviridae family with morphologic and structural similarities to other human herpesviruses. By adulthood, 95% to 99% of most of the world's population has demonstrable EBV antibodies, with seroconversion occurring before the age of 5 years in 50% of children in the United States. 1 EBV is the causative agent of infectious mononucleosis (IM) and has been implicated in other diseases, including Burkitt lymphoma and nasopharyngeal carcinoma and lymphoproliferative disorders in immunocompromised patients. The virus is generally acquired by oral transmission, with the initial infection occurring in the epithelial cells of the oropharynx. 2 The virus then selectively infects B lymphocytes migrating through the oropharyngeal lymphoid tissue, thus establishing a lifelong latent infection in the peripheral blood and other reticuloendothelial tissues.
The diagnosis of IM is based on clinical manifestations, which generally include sore throat, fever, lymphadenopathy, and malaise, in conjunction with laboratory test results. Owing to the high prevalence of EBV in the population, direct detection methods of the virus, such as culture and polymerase chain reaction, are time-consuming and expensive and generally not practical. For these reasons, most laboratory tests are based on the detection of antibodies to distinct EBVassociated antigens.
Several EBV antigens have been classified based on the phase of the viral replication cycle during which they are expressed. These include the viral capsid antigen (VCA), the EBV nuclear antigen (EBNA), and the early antigen (EA). The EAs are further classified as diffuse or restricted based on the different patterns of immunofluorescence staining exhibited by the 2 components. 3, 4 Antibody responses and their associated titers to specific EBV antigens correlate with different stages of IM. 1, [5] [6] [7] IgM antibodies to VCA are usually produced within 4 to 7 days after primary EBV infection and peak by 3 to 4 weeks, after which they decline rapidly and are usually undetectable after 12 weeks. VCA IgG antibodies are initially produced concurrently with IgM but decline slowly after peaking and last indefinitely. Antibodies to EA appear transiently for up to 3 months during the acute phase of IM in 85% of patients. 8, 9 There is a moderate rise in levels of antibodies to EA during reactivation, and they may remain elevated in chronic infection. The antibody response to EA in patients with IM is usually to the diffuse component, whereas silent seroconversion to EBV in children produces antibodies to the restricted component. 1, 6 Antibodies to EBNA, characteristically a late-onset response, are produced within 4 to 6 weeks of exposure and, like antibodies to VCA, persist indefinitely. 6, 7 In this study, we evaluated a multiplex Luminex-based (Luminex, Austin, TX) assay for the simultaneous detection of VCA IgG and IgM, EBNA IgG, and EA IgG antibodies. Results from this multiplex assay were compared with those of single-result enzyme-linked immunosorbent assays (ELISAs) for the same 3 antigens. Discrepant results were resolved by an indirect fluorescent antibody (IFA) assay, which is still considered the "gold standard" reference method.
Materials and Methods

Clinical Samples
This study included 158 serum samples submitted to our reference laboratory for EBV antibody testing. Patient study subjects consisted of 88 females ranging in age from younger than 1 year to 88 years, with a mean age of 31.6 years, and 70 males with an age range of 1 to 69 years and a mean age of 28.4 years. We also included 20 samples containing potentially interfering factors 10 in this study: 5 each of IgM+ samples for herpes simplex virus, cytomegalovirus, varicella zoster virus, and Toxoplasma gondii. In addition, 23 samples containing elevated concentrations of rheumatoid factor (RF) IgM were included. All patient samples included in this study were deidentified according to the University of Utah Institutional Review Board-approved protocol (No. 7275) to meet the Health Information Portability and Accountability Act patient confidentiality guidelines.
EBV Assays
Single-antigen ELISAs for EBV VCA IgM, VCA IgG, EBNA IgG, and diffuse EA IgG were purchased from DiaSorin (Stillwater, MN). The multiplex AtheNA Multi-Lyte EBV Test System and the IFA assays were provided free of charge by Inverness Medical Professional Diagnostics (Princeton, NJ). All assays used in this study have received US Food and Drug Administration clearance and are labeled for in vitro diagnostic use. The antigens used in the ELISAs were primarily synthetic peptides. A 56-amino-acid p18 protein containing immunodominant epitopes of a major component of the VCA complex [11] [12] [13] was used for the VCA IgG and IgM assays, The EBNA IgG assay uses a 59-amino-acid synthetic peptide containing several domains of the EBNA-1. The Gly-Ala repeat was excluded owing to its known cross-reactivity with autoantigens. The diffuse EA consists of a 47-kd recombinant polypeptide 14 expressed in Escherichia coli and then purified.
The antigens used in the multiplex assay were primarily affinity purified from virally infected cell lines, with each antigen coupled to microspheres containing specific amounts of 2 fluorescent fluorophobes. 15 Affinity-purified EBV VCA glycoprotein 125 was used in the IgG and IgM assays. The EA was also affinity purified with roughly equal parts of diffuse and restricted coupled to the same microsphere set. A recombinant protein of the EBNA-1 domain was used in the multiplex assay. In addition to the 3 antigen-coupled microspheres, 5 additional microsphere sets were included for quality control purposes. One was designed to detect binding of nonspecific and RF IgM antibodies in the patient sample, and the other 4 bead sets were used for intra-assay calibration.
All assays were performed with strict adherence to the manufacturers' instructions as detailed in the product inserts. For the ELISA IgG assays, patient samples were diluted 1:101 in the supplied serum diluent. We added 100 µL of the calibrators and diluted sample and control samples to the antigencoated microtiter plates. This step was followed by incubation at 37°C ± 2°C for 60 ± 5 minutes. After 4 wash cycles using an automated washer, 100 µL of horseradish peroxidase-conjugated antihuman IgG was added to each well. The microtiter plate was again incubated and washed as described before the addition of 100 µL of tetramethylbenzidine/hydrogen peroxide chromogen/substrate to each well, followed by incubation at room temperature (22°C-27°C) for 30 ± 2 minutes. This reaction was then stopped by the addition of 200 µL of 0.4N sulfuric acid, and the absorbance was read at 450/630 nm. The IgM ELISA used IgM capture via a surface-bound antihuman IgM (µ chain specific) monoclonal antibody. The patient VCA IgM antibodies were then detected by VCA p18 peptide antigen, which is linked to an anti-p18 monoclonal antibody conjugated to horseradish peroxidase.
For the multiplex assay, patient samples, control samples, and calibrator were diluted 1:21 in sample diluent. Next, 50 µL of the microsphere suspension was dispensed into each well of a 96-well filtration plate, to which 10 µL of the diluted samples, control samples, and calibrator were added. The microtiter plate was then thoroughly mixed using an orbital plate shaker and then incubated at room temperature (20°C-25°C) for 30 ± 10 minutes without shaking. The filter plate was then washed 3 times by vacuum filtration, followed by the addition of 150 µL of goat antihuman IgG (Fc chain specific) phycoerythrin conjugate to each well. The microtiter plate was then thoroughly mixed and incubated at room temperature for 30 ± 10 minutes. After the final incubation, the microtiter plate was placed on the Luminex 100 instrument, in which the microspheres were identified based on the fluorescent intensities of 2 internal fluorophores. The amount of patient IgG or IgM bound to the EBV antigen-coupled microspheres was determined by the intensity of the fluorescence generated by the antihuman IgG or IgM phycoerythrin-conjugated reporter antibody. The amount of fluorescence is proportional to the amount of patient antibodies bound to the microsphere. By using Intra-Well Calibration Technology, we used internal calibration bead sets to convert raw fluorescence into arbitrary units.
Data Analysis
Reference ranges for determining semiquantitative patient results based on the amount of antibody measured were taken from the package inserts and were different for the 2 assays. Reference ranges for the multiplex assay were as follows: less than 100 U/mL, negative, indicating no detectable IgG or IgM antibody to the particular marker; 100 to 120 U/mL, inconclusive, with the recommendation of the testing of a second sample at a later date; and more than 120 U/mL, positive, indicating that the specimen is positive for IgG or IgM antibody to the marker. Reference ranges for the ELISAs were slightly modified from those supplied by the manufacturer to include an inconclusive range and were as follows: 0.90 index value (IV) or less, negative, no significant level of detectable antibody; 0.91 to 0.99 IV, inconclusive, repeated testing in 10 to 14 days may be helpful; and 1.00 IV or greater, positive, indicating the presence of IgG or IgM antibodies to the marker.
To determine agreement, sensitivity, and specificity between the multiplex assay and the individual ELISAs, results were analyzed using 2 × 2 contingency tables. 16 All samples with discrepant results were repeated in duplicate on both assays. IFA testing was then performed on samples with discrepant results that were not resolved by repeated testing, with this result used in calculations as the "IFA-resolved" result. Samples with inconclusive results were not included in the calculations of clinical agreement, sensitivity, and specificity. The serologic status of EBV infection was determined by using the criteria outlined in ❚Table 1❚, which were derived from the literature. 1,5-9
Results
Comparison of Multiplex Assay With ELISA
Initial analysis of results compared the multiplex assay with ELISA for each individual EBV marker ❚Table 2❚. The multiplex assay and the ELISA were then compared individually with the IFA-resolved results ❚Table 3❚ and ❚Table 4❚, respectively.
Agreement for EBV VCA IgM between the multiplex and ELISA assay was an acceptable 86.6%. Sensitivity between the 2 assays, however, was poor (56.3%). This was due to a proportionally large number of samples (14) with positive results by ELISA but negative results with the multiplex assay. When compared with the IFA result, sensitivities improved for the ELISA (81.3%) and the multiplex assay (71.9%). Specificity compared with the IFA result was excellent for both assays, 96.7% and 98.4%, respectively.
The multiplex assay showed good agreement (92.8%) and sensitivity (99.2%) for EBV VCA IgG when compared with the ELISA assay, but specificity was poor (54.5%). The low specificity was due to 10 samples with positive results by the multiplex assay but negative results by ELISA. Compared with the IFA-resolved result, the specificity was 85.7% for the multiplex assay and 100.0% for the ELISA assay. The multiplex assay demonstrated greater sensitivity (99.3%) than the ELISA (94.9%) compared with the IFA result.
Comparing the 2 assays for EBNA IgG antibody responses resulted in an agreement of 90.3%, sensitivity of 100.0%, and specificity of 73.2%. When compared with the IFA result, the multiplex assay had greater sensitivity than the ELISA (100.0% vs 89.2%) but lower specificity (93.2% vs 100.0%), respectively.
Overall agreement between the multiplex and ELISA assays for EA IgG was 83.8%. There were 17 samples with positive results by ELISA but negative by the multiplex assay, yielding a sensitivity of 73.0%. Agreement compared with the IFA result was similar between the multiplex assay (92.8%) and ELISA (89.9%), but the specificity vs the IFA result was greater with the multiplex assay (96.3%) compared with ELISA vs the IFA assay (88.6%).
Evaluation of Serologic Status
The evaluation of a patient's EBV status is usually not based on results of an individual marker but on clinical 
Frequency of Uninterpretable Results
The inconclusive range was set at up to 20% more than the cutoff value for the multiplex assay and at 90% of the cutoff for the ELISA. For the most part, neither assay had many test interpretations with inconclusive results, fewer than 1% for VCA IgG and IgM and for EBNA. For EA, however, the multiplex assay reported 10.8% (17/158) of all results as inconclusive, with the ELISA having an inconclusive rate of 3.8% (6/158). In regard to serologic status, the multiplex assay only had 2 (1.3%) of 158 interpretations of "no applicable category," and the ELISA had 7 (4.4%).
Effects of RFs and Other Interferences
Of the 20 samples positive for IgM antibodies to herpes simplex virus, cytomegalovirus, varicella zoster virus, or T gondii, 6 (30%) gave positive results for the multiplex EBV VCA IgM assay. All 6 of these samples also contained elevated concentrations of RF IgM and were, therefore, analyzed with the additional RF samples as described next.
Of the 23 samples that contained elevated concentrations of RF IgM, 9 (39%) were reported as invalid results by the multiplexed EBV VCA IgM assay owing to elevated signals from the rheumatoid factor control microsphere ❚Table 8❚. An additional 9 (39%) were positive for the multiplex VCA IgM, and 5 (22%) were negative. Only 3 (13%) of the same 23 samples were positive by the IgM capture ELISA (Table 8) . When the 9 multiplex-positive samples were retested using an antihuman IgG polyclonal antibody in the serum diluent, 17 5 samples (marked with a double dagger in Table 8 ) changed from a positive to negative result, which agreed with the IgM capture ELISA result. Of the 4 samples that remained multiplex VCA IgM positive after IgG absorption, 2 were also positive by the IgM capture ELISA.
Discussion
Although IFA assay is still considered the gold standard for EBV serologic diagnosis, this technique has been widely replaced by ELISA methods for routine clinical laboratory use owing to its reliability and high-throughput analysis. Numerous studies have shown good concordance between the ELISA and IFA assay. 18, 19 The new generation of multiplex EBV assays offers additional advantages over ELISA, but their performance has not been established in the literature using the IFA assay for discrepancy resolution. 20 In this study, we evaluated the first Food and Drug Administration-cleared multiplex EBV assay in comparison with a well-established ELISA method and traditional IFA assay.
The ELISA gave a greater percentage of VCA IgM-positive results (32/158 [20.3%]) compared with the multiplex assay (25/158 [15.8%] ). The ELISA is based on the IgMcapture method, which generally results in a more specific but less sensitive assay compared with the method used by the multiplex assay in which the antigen is directly bound to the solid phase (microsphere) to which specific antibodies in the patient's serum sample bind. In our study, however, the ELISA method reported 7 additional positive results compared with the multiplex method. It could be assumed, therefore, that the discrepancies are more likely due to differences in the antigen used by the 2 assays, synthetic p18 peptide for ELISA and affinity-purified VCA glycoprotein 125 for the multiplex assay.
Conversely For the EA, the ELISA assay used a 47-kd recombinant polypeptide for the diffuse component only but had a higher positivity rate, 43.0% (68/158), than the multiplex assay, 33.5% (53/158), which contained affinity-purified antigens for the restricted and diffuse antigen components.
Based on the pattern of antibody responses to the different viral antigens produced during the EBV replication cycle, the serologic profile of a patient can be classified as susceptible to infection or as having an early, acute, recent or subacute, or past infection (Table 1 ). There was good concordance for the serologic profiles between the ELISA and multiplex methods (89.9%) when the discrepant results were resolved by IFA assay, the gold standard. Of the 18 major discrepant results (Table 7) , the multiplex assay result was in agreement with the IFA result in 7 cases, ELISA and IFA results were in agreement in 5 cases, and in 6 cases, the IFA result agreed with neither the multiplex nor ELISA result. The most frequent major discrepancy between the assays was profiles regarded as susceptible (negative for all antigens) by the ELISA but classified as a past infection by the multiplex assay owing to VCA IgG-and EBNA-positive responses. Overall, the ELISA had lower positivity rates for VCA IgG and EBNA, leading to a greater number of susceptible profiles than the multiplex assay, but a higher number of VCA IgM-positive results giving rise to more acute or recent infection profiles than the multiplex assay.
With the exception of EA, both assays reported minimal inconclusive results, which may lead to less repeated testing and confusion in the interpretation of serologic status. The multiplex assay had 5 fewer patient antibody profiles giving an uninterpretable status compared with the ELISA.
RFs are autoantibodies of any isotype with specificity for the Fc portion of IgG. In IgM serologic assays in which the antigen is bound to the solid phase, such as the multiplex VCA assay, specific IgG antibodies present in the serum bind to the antigen, presenting a site for RF to bind. RF of the IgM class may then be recognized by the anti-IgM conjugate, giving rise to a false-positive IgM reaction. 17 The RF control microsphere contained in the multiplex VCA IgM assay was effective in identifying samples with highly elevated concentrations of RF IgM by flagging these samples as invalid, but it did not identify samples with moderate concentrations of RF IgM, which seemed to cause false-positive results in the multiplex assay. IgM RF concentrations of more than 26 IU/mL are considered clinically significant, but the amount of RF required to cause assay interference has not been defined and would most likely vary between assays. Seven of multiplex IgM-positive results shown in Table 8 were most likely falsely positive owing to IgM RF because they were negative by the IgM-capture ELISA, which is not prone to RF interference. This assumption is further supported as 5 of those samples had negative results after treatment with an IgG-absorbent serum diluent. Therefore, at least 5 of the VCA IgM discrepant results, which were positive by the multiplex assay and negative by the ELISA (Table 2) , could be attributed to IgM RF interference.
The multiplex test system uses the Intra-Well Calibration Technology that uses a multipoint standard curve contained within the bead mix. In addition to the assay controls, this technology generates a 4-point standard curve in each reaction to internally calibrate each well of the assay. Regression analysis of the internal standards is performed, allowing the software to adjust the calculated unit values based on the unique characteristics of the patient serum sample. The software also minimizes front-to-back intra-assay variation by using these internal controls.
The multiplex assay also has the advantage of reporting IgG results for all 3 antigens from a single reaction, resulting in reagent, labor, sample volume, and storage space savings. The VCA IgM assay is performed separately, but the same sample dilutions can be used for both IgG and IgM assays. There are several options for automating the entire multiplex procedure, but these were not evaluated in the present study. The multiplex system provides an accurate and cost-effective system for the detection of antibodies to the standard EBV markers.
